UCLH - University College London Hospitals NHS Foundation Trust

UCLH - University College London Hospitals NHS Foundation Trust University College London Hospitals NHS Foundation Trust, one of the largest NHS trusts in the UK, providing acute & specialist services in 6 hospitals.
(1480)

UCLH provides first-class acute and specialist services in six hospitals in central London. University College Hospital (incorporating the Elizabeth Garrett Anderson Wing, University College Hospital Macmillan Cancer Centre, University College Hospital Grafton Way Building and University College Hospital at Westmoreland Street)

Royal London Hospital for Integrated Medicine

Royal National ENT and

Eastman Dental Hospitals

National Hospital for Neurology and Neurosurgery at Queen Square and Cleveland Street

Institute of Sport and Exercise Health

Hospital for Tropical Diseases

Our mission is to deliver top-quality patient care, excellent education and world-class research. In partnership with University College London (UCL) we are one of the country’s five comprehensive biomedical research centres. We are a member of UCL Partners which brings together some of the UK's world-renowned medical research centres and hospitals.

Congratulations to our UCLH colleagues Dr Urshla “Oosh” Devalia and Professor Sarah Tabrizi who have both been recognise...
12/06/2026

Congratulations to our UCLH colleagues Dr Urshla “Oosh” Devalia and Professor Sarah Tabrizi who have both been recognised in the King’s Birthday Honours 2026 list.

Dr Devalia has been awarded an OBE in recognition of her contribution to children and young people’s oral health across the UK and Professor Tabrizi has been awarded an CBE for services to people with Huntington's Disease (HD).

UCLH chief executive David Probert said: “Congratulations to Dr Devalia and Professor Tabrizi. It is fantastic to see your hard work, passion, and expertise recognised in this way, and we are very grateful to your contributions to our patients and services at UCLH.”

Read more: https://buff.ly/MWumHK5

A new, life-extending drug for ovarian cancer which was trialled at UCLH is now available on the NHS.It is the first new...
12/06/2026

A new, life-extending drug for ovarian cancer which was trialled at UCLH is now available on the NHS.

It is the first new addition to NHS treatment for ovarian cancer in over 20 years, following an announcement by NHS England.

Dr Rowan Miller (pictured), who ran the clinical trials at UCLH in research supported by the National Institute for Health and Care Research Biomedical Research Centre at UCLH, said: "Finally, there's a drug that's available, that improves survival for this group of patients and in addition, the patients get on with the treatment well and find it easier to manage than standard chemotherapy.”

Find out more: https://buff.ly/02kel6U

“It’s like night and day,” says Katie Tinkler of her life before and after CAR T cell therapy. She suffered from lupus f...
12/06/2026

“It’s like night and day,” says Katie Tinkler of her life before and after CAR T cell therapy. She suffered from lupus for years before she went into remission, and credits her participation in the CARLYSLE trial with changing her life. “I can participate in life now,” she says.

The pioneering clinical trial led by UCLH and UCL is showing early promise for people with severe lupus who have exhausted existing treatment options.

Early results from the ongoing Phase I CARLYSLE trial, sponsored by Autolus, have been encouraging. As of November 2025, nine adults with severe, treatment-resistant lupus had received the treatment. All had highly active disease despite multiple previous therapies, and most had lupus nephritis, a serious form of the disease that affects the kidneys.

Researchers found that five of the first six patients treated at the lower dose achieved remission according to standard lupus criteria, with improvements emerging within months of treatment.

Patients also experienced rapid reductions in disease activity, alongside improvements in important laboratory markers associated with lupus.

Katie hopes her experience offers encouragement to others living with severe autoimmune disease. Meanwhile, UCLH and partners are continuing work on severl clinical trials testing CAR T cell therapy in autoimmune diseases in the hope of finding new ways of improving patients’ lives.

Read more: https://buff.ly/y9CPuAZ

COVID-19 can be very dangerous for older adults. We have walk-in availability, Monday to Friday, at our vaccine clinic f...
10/06/2026

COVID-19 can be very dangerous for older adults.

We have walk-in availability, Monday to Friday, at our vaccine clinic for the COVID-19 spring booster. If you are eligible, or you know someone who may be vulnerable, please come forward for your vaccine before 30 June.

View clinic details and opening times: buff.ly/JX9SmxD

Pleased to support staff networks including Proud making UCLH - University College London Hospitals NHS Foundation Trus...
09/06/2026

Pleased to support staff networks including Proud making UCLH - University College London Hospitals NHS Foundation Trust a more inclusive place to work.

COVID-19 can be very dangerous for older adults. We have walk-in availability, Monday to Friday, at our vaccine clinic f...
05/06/2026

COVID-19 can be very dangerous for older adults.

We have walk-in availability, Monday to Friday, at our vaccine clinic for the COVID-19 spring booster. If you are eligible, or you know someone who may be vulnerable, please come forward for your vaccine before 30 June.

View clinic details and opening times: buff.ly/KL6V64h

Today, we are proud to launch our new five-year strategy, which sets out the motivation that drives us, our purpose as a...
04/06/2026

Today, we are proud to launch our new five-year strategy, which sets out the motivation that drives us, our purpose as an organisation and our ambition for the next five years.

Our strategy outlines how we will transform lives through excellence in by placing patients, staff and partnership working at the heart of everything we do.

David Probert, chief executive, said: “I am really pleased that we are launching our new five-year strategy, which sets out a bold and exciting future for UCLH.

"We want to turn this strategy into real, lasting improvements for patients, staff and partners so that we continue to transform lives through excellence in healthcare.”

Find out more and read our strategy here: www.uclh.nhs.uk/strategy

Happy ! We are incredibly grateful to everyone who volunteers with us. Last year, 735 people gave up their time to help...
02/06/2026

Happy !

We are incredibly grateful to everyone who volunteers with us. Last year, 735 people gave up their time to help others, and this had a huge impact on patient experience.

Together, our volunteers gave over 36,000 hours of their time to UCLH. 287 of those volunteers were new to UCLH, reflecting the generosity and enthusiasm of our local community.

Alacoe (pictured right), who gives up her time as a Paediatric and Adolescent Support Volunteer on T11 and T12, said, “I’ve been volunteering at UCLH for nearly a year, having finished my undergraduate degree in psychology.

"The staff have really made me feel part of the team here. Volunteering has allowed me to meet and support a wide range of people from diverse backgrounds. The variety is brilliant, and no two days are the same!”

Thank you for making a difference to patients, families and visitors💙

Early results show a new immunotherapy medicine for Alzheimer’s disease is safe and researchers are hopeful it may impac...
01/06/2026

Early results show a new immunotherapy medicine for Alzheimer’s disease is safe and researchers are hopeful it may impact on disease progression.

UCLH’s Professor Catherine Mummery is leading the study into ImmunoBrain's investigational medicine that targets an immune pathway that researchers believe may play a role in Alzheimer’s disease and other neurological diseases.

Professor Mummery said: "There remains a significant unmet need for disease-modifying therapies that address the underlying biology of Alzheimer's Disease. Early evidence suggests that short, intermittent exposure to immune checkpoint modulation potentially offers a new therapeutic approach for Alzheimer's disease by activating the peripheral immune system to help restore the brain's natural repair process. I look forward to seeing additional clinical data for this program."

Read more: https://www.uclh.nhs.uk/news/new-brain-repair-drug-shows-promising-early-results-alzheimers

Address

235 Euston Road
London
NW12PG

Website

Alerts

Be the first to know and let us send you an email when UCLH - University College London Hospitals NHS Foundation Trust posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organisation

Send a message to UCLH - University College London Hospitals NHS Foundation Trust:

Shortcuts

Share